Citigroup Begins Coverage on Radius Health (RDUS)
Stock analysts at Citigroup started coverage on shares of Radius Health (NASDAQ:RDUS) in a research note issued to investors on Wednesday, MarketBeat.com reports. The firm set a “neutral” rating and a $30.00 price target on the biopharmaceutical company’s stock. Citigroup’s price objective would indicate a potential upside of 12.36% from the company’s current price.
A number of other analysts have also commented on the company. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Cantor Fitzgerald restated a “buy” rating and issued a $58.00 price target on shares of Radius Health in a report on Friday, November 3rd. Jefferies Group cut their price target on Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 3rd. BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Maxim Group restated a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. Radius Health currently has a consensus rating of “Hold” and an average price target of $48.00.
Radius Health (NASDAQ:RDUS) traded down $0.57 during mid-day trading on Wednesday, reaching $26.70. The company’s stock had a trading volume of 1,139,199 shares, compared to its average volume of 962,975. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. Radius Health has a 52-week low of $24.66 and a 52-week high of $55.00.
In related news, major shareholder Growth N. V. Biotech bought 50,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average price of $26.25 per share, with a total value of $1,312,500.00. Following the completion of the transaction, the insider now owns 5,698,799 shares in the company, valued at $149,593,473.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jose Carmona bought 3,000 shares of the stock in a transaction that occurred on Thursday, September 14th. The stock was bought at an average cost of $32.83 per share, for a total transaction of $98,490.00. Following the transaction, the chief financial officer now owns 3,000 shares of the company’s stock, valued at approximately $98,490. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 367,678 shares of company stock worth $11,746,498. 15.00% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board acquired a new stake in shares of Radius Health in the second quarter valued at about $1,176,000. Candriam Luxembourg S.C.A. increased its position in shares of Radius Health by 23.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 142,000 shares of the biopharmaceutical company’s stock valued at $5,474,000 after acquiring an additional 27,000 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Radius Health by 4.5% in the second quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock valued at $142,281,000 after acquiring an additional 135,071 shares during the last quarter. State Street Corp increased its position in shares of Radius Health by 12.9% in the second quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock valued at $84,473,000 after acquiring an additional 213,399 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Radius Health by 10.0% in the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock valued at $130,881,000 after acquiring an additional 262,896 shares during the last quarter.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.